Alica S Sparling1, Eunyoung Song1, Heidi D Klepin1, Kristie L Foley1. 1. 1 Department of Economics, Davidson College, Davidson, NC 28035, USA ; 2 Department of Social Sciences and Health Policy, Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA ; 3 Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA ; 4 Cancer Prevention and Control Program, Comprehensive Cancer Center, Department of Social Sciences and Health Policy, Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.
Abstract
BACKGROUND: Adjuvant chemotherapy for colon cancer has been linked to patient and provider characteristics but little is known about whether distance to chemotherapy providers constitutes an obstacle to chemotherapy. METHODS: A total of 1,184 Medicaid patients diagnosed with colon cancer in North Carolina in 1999-2002 comprised the sample. Data from the N.C. Central Cancer Registry, N.C. Medicaid Claims, American Hospital Directory and US Census were merged. Logistic regression models were used to estimate the association between chemotherapy receipt and the distance to nearest chemotherapy provider. RESULTS: Compared to the referent group of SEER-staged II (local) cancer patients living less than 2 miles from the nearest chemotherapy provider, the odds of receiving chemotherapy fell as the distance to the nearest provider increased. The odds ratio (OR) for those living ≥5 to <15 miles away was 0.13 [95% confidence intervals (CI), 0.04-0.39], and OR for those living ≥15 miles away was 0.06 (95% CI, 0.01-0.52). Patients diagnosed with regional, SEER-staged III (regional) cancer were less likely to receive chemotherapy if they lived in rural areas more than 20 miles away from the nearest provider (OR =0.08; 95% CI, 0.01-0.72). However, we found no evidence of association between chemotherapy receipt and distance to the nearest provider for regional cancer patients living in urban areas and those living in rural areas within 20 miles from the nearest chemotherapy provider. CONCLUSIONS: Distance to provider may be an obstacle to chemotherapy for some groups of low-income colon cancer patients. Relieving travel burdens of rural patients living far from providers may help Medicaid increase guideline-consistent adjuvant care for regional cancer patients.
BACKGROUND: Adjuvant chemotherapy for colon cancer has been linked to patient and provider characteristics but little is known about whether distance to chemotherapy providers constitutes an obstacle to chemotherapy. METHODS: A total of 1,184 Medicaid patients diagnosed with colon cancer in North Carolina in 1999-2002 comprised the sample. Data from the N.C. Central Cancer Registry, N.C. Medicaid Claims, American Hospital Directory and US Census were merged. Logistic regression models were used to estimate the association between chemotherapy receipt and the distance to nearest chemotherapy provider. RESULTS: Compared to the referent group of SEER-staged II (local) cancerpatients living less than 2 miles from the nearest chemotherapy provider, the odds of receiving chemotherapy fell as the distance to the nearest provider increased. The odds ratio (OR) for those living ≥5 to <15 miles away was 0.13 [95% confidence intervals (CI), 0.04-0.39], and OR for those living ≥15 miles away was 0.06 (95% CI, 0.01-0.52). Patients diagnosed with regional, SEER-staged III (regional) cancer were less likely to receive chemotherapy if they lived in rural areas more than 20 miles away from the nearest provider (OR =0.08; 95% CI, 0.01-0.72). However, we found no evidence of association between chemotherapy receipt and distance to the nearest provider for regional cancerpatients living in urban areas and those living in rural areas within 20 miles from the nearest chemotherapy provider. CONCLUSIONS: Distance to provider may be an obstacle to chemotherapy for some groups of low-income colon cancerpatients. Relieving travel burdens of rural patients living far from providers may help Medicaid increase guideline-consistent adjuvant care for regional cancerpatients.
Authors: John F Scoggins; Catherine R Fedorenko; Sara M A Donahue; Dedra Buchwald; David K Blough; Scott D Ramsey Journal: J Rural Health Date: 2011-03-31 Impact factor: 4.333
Authors: Lisa P Spees; Stephanie B Wheeler; Mahesh Varia; Morris Weinberger; Christopher D Baggett; Xi Zhou; Victoria M Petermann; Wendy R Brewster Journal: Gynecol Oncol Date: 2018-11-12 Impact factor: 5.482
Authors: Jessica L King; Kimberly G Wagoner; Cynthia K Suerken; Eunyoung Y Song; Beth A Reboussin; John Spangler; Stephannie Walker; Jennifer Cornacchione Ross; Mark Wolfson; Erin L Sutfin Journal: Subst Use Misuse Date: 2020-09-24 Impact factor: 2.164
Authors: Shelley A Jazowski; Isabelle P Sico; Jennifer H Lindquist; Valerie A Smith; Hayden B Bosworth; Susanne Danus; Dawn Provenzale; Michael J Kelley; Leah L Zullig Journal: BMC Health Serv Res Date: 2021-04-13 Impact factor: 2.655
Authors: Chelsea A Obrochta; Humberto Parada; James D Murphy; Atsushi Nara; Dennis Trinidad; Maria Rosario Happy Araneta; Caroline A Thompson Journal: PLoS One Date: 2022-10-05 Impact factor: 3.752